1.The influence of Montelukast in the treatment of patients with bronchial asthma on immune response
Chinese Journal of Primary Medicine and Pharmacy 2016;(1):4-6,7
Objective To explore the influence of Montelukast in the treatment of patients with bronchial asthma on the immune response,and to provide the basis for clinical treatment.Methods 104 patients with bronchial asthma were selected.They were randomly divided into the treatment group and the control group by the random number table method,with 52 cases in each group.The control group patients were given conventional treatment,and the treatment group were treated with Montelukast on the basis of the control group.Daytime symptom and night symptom of the two groups before and after treatment were assessed,and airway reactivity by the early respiratory resistance (Rrsc)and response threshold (Dmin)were evaluated.And the change of T lymphocyte subsets before and after the treatment were detected.Results The day symptom scores,night symptom scores and Rrsc of the treatment group after treatment were respectively (0.49 ±0.12)points,(0.66 ±0.20)points and (2.19 ±0.38)cmH2 O,which were lower than those of the control group after treatment(t =7.90,8.13,8.24,all P <0.05).The data of the two groups after treatment were lower than those before treatment,the differences were statistically significant (t =9.38,8.66, 9.17,9.41,8.90,9.24,all P <0.05).Dmin of the treatment group after treatment was (8.29 ±0.44)U,which was higher than that of the control group after treatment,the data of the two groups after treatment were higher than those before the treatment,the differences were statistically significant(t =7.41,8.23,all P <0.05).CD +4 and CD +4 /CD +8 of the treatment group after treatment were (43.03 ±5.02)% and(1.79 ±0.34),respectively,which were higher than those of the control group after treatment (t =9.81,10.04,all P <0.05 ).The data of the two groups after treatment were higher than those before the treatment,the differences were statistically significantly different (t =10.62,10.33,10.93,10.62,all P <0.05).CD +8 of the treatment group after treatment was (23.38 ±3.88)%, which was lower than that of the control group after treatment(t =9.93,P <0.05),the data of the two groups after treatment were lower than those before treatment,the differences were statistically significant (t =9.16,9.29,all P <0.05 ).Conclusion Montelukast treatment of bronchial asthma can significantly improve symptoms and immune function of patients,it is worthy of clinical popularization and application.
2.The study of Anti-cyclic citrullinated peptide antibodies and rheumatoid factors with the disease activity of rheumatoid arthritis
Yili GU ; Yuming CHEN ; Ling LU ; Mailing XU ; Hejian ZOU
Chinese Journal of Rheumatology 2003;0(11):-
Objective To compare the correlation between ACCP, IgA-RF, IgG-RF, IgM-RF and disease activity, bone erosion of rheumatoid arthritis. Method The correlation analysis between ACCP, IgA-RF, IgG-RF, IgM-RF and disease activity score (DAS), Ritchie′s articular index (RAI) were made SPSS software. ACCP, IgA-RF, IgG-RF, IgM-RF were compared between patients with erosive disease and with non-erosive disease. Results IgM-RF was associated with RAI, but ACCP, IgA-RF and IgG-RF were not associated with RAI. The above parameters were not associated with DAS by Spearman correlation analysis. The association between above parameters and bone erosion was not detected, however. Conclusion IgM-RF is associated with disease activity. ACCP and IgA-RF, IgG-RF are not associated with disease activity. No association is found between above parameters and bone erosion.
3.Correlation of anti-gangl ioside antibodies with clinical features of systemic lupus erythematosus
Minrui LIANG ; Xiangjun CHEN ; Jian QIAO ; Hejian ZOU
Chinese Journal of Rheumatology 2010;14(9):597-601
Objective To explore the correlation of anti-ganglioside antibodies with clinical features of systemic lupus erythematosus (SLE). Methods Samples of serum were collected from 48 patients with SLE. Three were male and 45 were female. Their average age was 33±12 (15~59). The serum anti-ganglioside antibodies of 10 patients with rheumatoid arthritis (RA), 4 with Sj(o)gren's syndrome (SS), 1 patient with mixed connective tissue disease (MCTD), 1 with polymyositis (PM), and 97 healthy controls(HC) were alsoexamined. Levels of anti-GM1-IgM/IgG, anti-GQ1b-IgM/IgG antibodies in the serum were examined by amodified ELISA. Anti-dsDNA-IgG antibody of SLE was tested according to the ELISA kit protocol. The associations of anti-GM1-IgM/IgG and anti-GQ1b-IgM/IgG antibodies with clinical features were analyzed. x2test, one-way ANOVA, Dunnett t-test were used for statistical analysis. Results By using modified ELISA,the upper limit of reference value of anti-GM1-IgM/IgG antibodies, anti -GQ1b-IgM/IgG antibodies in the serum of Chinese SLE patients were 0.411, 0.408, 0.481 and 0.441 res-pectively. 19% patients with SLE were sero-positive for anti-GM1 antibody, 4% for IgM antibody isotype and 15% for IgG antibody isotype. Anti-GM1-IgG antibody was significantly increased in the serum of patients with SLE (0.33±0.09), higher than that of the HC (0.27±0.05) (P<0.05), RA (0.29±0.08), SS(0.27±0.06), PM ( 0.288 ), but one of the MCTD( 0.423 ).There was no significant associations between anti-GM1-IgM/IgG, anti-GQ1b-IgM/IgG antibodies and NPSLE and anti-dsDNA-IgG antibody (P>0.05). Conclusion Peripheral autoimmune response against GM1 can be detected in SLE patients, and it may be involved in the pathogenesis of SLE. No association of antiGM1-IgM/IgG antibodies or anti-GQ1b-IgM/IgG antibodies with clinical features of SLE can be discovered.
4.Application of ICF-CY in Rehabiliation for Children with Cerebral Palsy: A Case Report
Hejian LIU ; Zhuoying QIU ; Wenping ZHOU ; Wenhua CHEN
Chinese Journal of Rehabilitation Theory and Practice 2014;20(1):6-10
Objective To apply the theory and model of International Classification of Functioning, Disability and Health (Children and Youth Version) (ICF-CY) in rehabilitation for children with cerebral palsy. Methods A case accepted rehabilitation in the framework of ICF-CY was reported. Results and Conclusion The framework of ICF-CY can be used in rehabilitation for children with cerebral palsy.
5.Application of Children's Rehabilitation Management System in Occupational Therapy for Cerebral Palsy
Zhengqing GE ; Hejian LIU ; Wen ZHANG ; Yun MIU ; Wenhua CHEN
Chinese Journal of Rehabilitation Theory and Practice 2013;19(3):252-254
Objective To investigate the significance of the Children's Rehabilitation Management System (ICR 2.0) for occupational therapy (OT) for cerebral palsy (CP). Methods 60 children with CP were divided into group A (n=30) and group B (n=30). The group A accepted OT program assisted with ICR 2.0, and the group B accepted OT program drawn by therapists experientially. They were assessed with Enjoji infant development scale and Fine Motor Function Measure (FMFM) before and 3 months after treatment. Results There was no significant difference in development months and the fine motor between 2 groups before treatment (P>0.05). Both the development and fine motor improved after treatment (P<0.001), and improved more in the group A than in the group B (P<0.05). Conclusion ICR 2.0 assisted OT program can further improve the recovery of children with CP.
6.Status and Unmet Needs of Family Rehabilitation for Children with Disabilities
Hejian LIU ; Guiyuan WANG ; Guangyang PENG ; Chen WANG ; Xiaodong WANG ; Bin ZOU ; Yang NIU ; Wenhua CHEN
Chinese Journal of Rehabilitation Theory and Practice 2014;(9):820-822
Objective To investigate the current status of family rehabilitation for children with disability and the unmet needs of habilitation/rehabilitation for their parents. Methods Family Rehabilitation Needs Survey Questionnaire was used to investigate 186 families of the children with disability from 5 rehabilitation institutions in 4 provinces. Results Most families accepted family rehabilitation, including family support, developed rehabilitation scheme, telephone counseling, real-time guidance and appointment for family rehabilitation. Most families would spent 1-2 hours a day for the family rehabilitation, and prefer the rehabilitation of gross motion. However, the rehabilitation agencies played less importance on supports of family rehabilitation. Conclusion The family rehabilitation supports needs to be improved in specification of rehabilitation process, developing rehabilitation scheme and quality control.
7.The association of BANK1 single nucleotide polymorphisms with rheumatoid arthritis in Chinese Han population
Ning KONG ; Zhiyuan WU ; Lei JIANG ; Yuming CHEN ; Ming GUAN ; Hejian ZOU
Chinese Journal of Rheumatology 2012;16(2):82-86
ObjectiveTo investigate the association of BANK1 single nucleotide polymorphisms (SNPs) with rheumatoid arthritis(RA) in Chinese Han. MethodsTwo hundreds and twenty-one RA patients and 310 healthy controls who were Chinses Han population from Huashan Hopital and Changzheng Hospital in Shanghai,China were included.DNAs were extracted from peripheral whole blood for study.Samples were genotyped for three variants rs10516487,rs17266594 and rs3733197 in BANK1 by unlabelled probe high resolution melting (HRM) assay.The genotype frequencies of the detected polymorphisms were analyzed in relation to RA and the production of autoantibodies in RA patients.ResultsThe Tr genotype frequency was much higher in RA patients than in healthy controls(X2=6.241,P=0.044).The frequencies of rs10516487 G allele,rs17266594 T allele and rs3733197 G allele were increased among RA patients compared with healthy controls,although they didn't reach statistical significance.The rs10516487 and rs17266594 were found in strong linkage disequilibrium(D'=0.993,r2=0.985).And also the major TGG haplotype of 3-SNP was significantly associated with RA patients[P=0.037,OR =1.345,95%CI (1.018-1.776)].ConclusionBANK1 rs17266594 polymorphism is susceptible to RA,while rs10516487 and rs17266594 are linked in Chinese Han population.BANK1 SNPs TGG haplotype may contribute to RA susceptibility,too.
8.A comparative study of aripiprazole treatment for co-morbid attention deficiency hyperactivity disorder in ;children with Tourette syndrome
Hejian YANG ; Fuye ZHANG ; Baohai SHI ; Yameng LIU ; Xinli YANG ; Liping CHEN ; Sumei ZHANG
Chinese Journal of Nervous and Mental Diseases 2016;42(3):156-160
Objective To evaluate the efficacy and safety of aripiprazole treatment for co-morbid attention defi?ciency hyperactivity disorder (ADHD) in children with Tourette syndrome (TS). Methods Forty four TS children with co-morbid ADHD were randomly divided into aripiprazole group and haloperidol group. The aripiprazole group and halo?peridol group received aripiprazole and haloperidol treatment for 12 weeks, respectively. Yale global tic severity scale (YGTSS) and Conners parent symptom questionnaire (PSQ) were used to assess the tic and ADHD symptoms before, 2, 4, 8 and 12 weeks after treatment. Side effects were recorded weekly. Results Repeated measure ANOVA indicated that the main effects of groups was not significant to the YGTSS scores (P>0.05), but significant to the PSQ scores (P<0.05). After 12-week treatment, the YGTSS scores between two groups were not significantly different (P>0.05). The PSQ scores of aripiprazole group were significantly lower than that of haloperidol group. The adverse reactions of aripiprazole group were milder compared with the haloperidol group (P<0.05). Conclusions The present study demonstrates that aripipra?zole has the same efficacy in the treatment of tics as haloperidol, improves co-morbid ADHD symptoms, and its adverse reactions are much less compared with haloperidol.
9.The determination of a new single nucleotid polymorphism intron 5 (+4668) with high-resolution melting technology in gout patients
Shuangchun LIU ; Ming GUAN ; Yuming CHEN ; Jiong ZHANG ; Xinju ZHANG ; Xiaoye GU ; Weizhe MA ; Hejian ZOU
Chinese Journal of Rheumatology 2010;14(6):377-380
Objective To investigate a new single nucleotid polymorphism (SNP) intron5(+4668C/T) in SLC22A12 in primary gout patients and the association between clinical characteristics and genotypes. Methods One hundred and one primary gout patients and 186 healthy subjects were recruited into this study. Blood pressure, body mass index (BMI) was recorded. Serum uric acid, glucose, lipid and creatinine were detected. DNA was extracted from peripheral blood to amplify the fragment located in intron 5. The genotypes of SLC22A12 can be detected with high-resolution melting (HRM) assay, followed by sequencing analysis. Chi-square test was used for statistical analysis. Results ① A new SNP in intron 5 of SLC22A12 was identi-fied successfully by HRM, which was defined as intron 5 (+4668C/T). CC, CT and TT genotypes were unam-biguously distinguished with HRM technology, which was fully concordant with sequencing. ②The genotypes of CC, CT and TT in male and female groups were 28.1%, 33.7%, 38.2% and 20.0%, 47.1%, 32.9%, respectively.③ However, no significant differences of genotype distribution were found concerning BMI, blood pressure, creatinine, total cholesterol and triglyceride in both male group and female group. But the serum uric acid levels in the CC genotype were significantly higher than those with the CT+TT genotypes. ④ The genotype frequencies of CC and CT+TT in high uric acid group were remarkably different from those in low uric acid group (21.2%, 78.8%,; 35.0%, 65.0%; P<0.05). Conclusion A new SNP has been successfully discovered with HRM technology with simplicity, rapidity and accuracy. T allele of intron 5 (+4668C/T) may be a genetic protective factor for hyperuricemia among Chinese population.
10.The activity of blood cholinesterase in rats exposed to dimethypo after drug intervention.
Weiguo WAN ; Mailing XU ; Hejian ZOU ; Ailing LU ; Xinyu SHEN ; Yuming CHEN
Chinese Journal of Industrial Hygiene and Occupational Diseases 2002;20(6):419-421
OBJECTIVETo investigate the activity of ChE in rats poisoned by dimehypo and then treated with pralidoxime methylchloride or unithiol.
METHODRats were divided into control group (dimehypo); intervention groups [dimehypo plus pralidoxime methylchloride or dimehypo plus unithiol (sodium dimercaptopropanesulphonate)]. Rats were dosed with 4 different doses of dimehypo: 1/16, 1/8, 1/4 and 1/2 of LD50 respectively(the LD50 of dimehypo is 342 mg/kg). After being poisoned with dimehypo orally, rats were immediately injected intramuscularly with pralidoxime methylchloride or unithiol. The activity of ChE in blood was detected before and 1/2, 1, 2, 4 and 24 h after poisoning in dimehypo and intervention groups.
RESULTThe ChE activity of four dose subgroups at 1 h after poisoning were (1.04 +/- 0.21), (0.84 +/- 0.12), (0.71 +/- 0.12), (0.66 +/- 0.07) U/ml respectively; the ChE activity of pralidoxime methylchloride intervention groups were (1.01 +/- 0.18), (1.17 +/- 0.11), (1.01 +/- 0.04), (1.03 +/- 0.12) U/ml respectively; and the ChE activity of unithiol intervention groups were (1.15 +/- 0.15), (1.26 +/- 0.27), (1.08 +/- 0.08), (1.04 +/- 0.12) U/ml respectively. The inhibited ChE in blood was recovered by either treatment with pyraldoxime methylchloride or unithiol. These two drugs had similar effects of recovering the activity of ChE(P > 0.05), but at higher doses(1/4 and 1/2 of LD50) the effects of both were not so good.
CONCLUSIONPralidoxime methylchloride and unithiol could partly recover the activity of ChE inhibited by dimehypo.
Animals ; Antidotes ; pharmacology ; Cholinesterase Inhibitors ; poisoning ; Cholinesterases ; blood ; Dose-Response Relationship, Drug ; Insecticides ; poisoning ; Pralidoxime Compounds ; pharmacology ; Rats ; Unithiol ; pharmacology